What Is Edotreotide? Definition and What Research Reports

Definition

Edotreotide is the international nonproprietary name for DOTA-Tyr³-octreotide, commonly abbreviated DOTATOC. It is a laboratory-made peptide: a cyclic eight-amino-acid somatostatin analogue (the octreotide scaffold, with tyrosine substituted at position 3) that has been covalently linked to DOTA, a macrocyclic chelating cage. The peptide half provides binding affinity for somatostatin receptors, particularly subtype 2, which are densely expressed on many neuroendocrine tumour cells; the DOTA half grips a radioactive metal ion. Edotreotide is therefore almost never discussed on its own in the literature — it appears as a radiolabelled complex, written in forms such as [⁶⁸Ga]Ga-edotreotide, [¹⁷⁷Lu]Lu-edotreotide or ⁹⁰Y-edotreotide. A drug monograph catalogued under the entry "Edotreotide Gallium Ga-68" describes the gallium-68 labelled form used as a positron-emitting imaging agent (PMID 33104320). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, imaging or treatment.

What Class of Molecule Is It, and Where Does It Come From?

Edotreotide belongs to the class of chelator-conjugated peptide radiopharmaceutical precursors. It is fully synthetic. Its biological ancestor is somatostatin, a natural regulatory hormone whose very short circulating half-life made it impractical as a targeting molecule; octreotide, a stabilised cyclic analogue, became the template, and edotreotide is that template modified with a tyrosine residue and bolted to DOTA.

Because the chelator accepts different metals without changing the peptide's targeting behaviour, edotreotide is often described in the literature as one half of a theranostic pair: the same carrier peptide can be used to visualise receptor-positive tissue and, with a different isotope, to deliver radiation to it.

How the Term Is Used in Peptide Research

In published papers, "edotreotide" almost always appears with its isotope prefix, and readers will encounter several conventions for the same substance:

• DOTATOC — the chemical shorthand, used interchangeably with edotreotide in the systematic-review literature on lutetium-177 labelled preparations (PMID 41204752).
• [⁶⁸Ga]Ga-edotreotide — the PET/CT imaging form; a 2025 radiochemistry paper worked on a shortened radio-thin-layer-chromatography method for assessing the radiochemical purity of this preparation, referred to by the kit name Somakit-TOC (PMID 40358768).
• [¹⁷⁷Lu]Lu-edotreotide and ⁹⁰Y-edotreotide — the therapeutic forms studied under the umbrella term peptide receptor radionuclide therapy (PRRT).

A second research context is production chemistry rather than clinical outcome. Researchers described a scalable cold-kit radiolabelling approach for preparing [⁶⁸Ga]Ga-edotreotide using aliquoting and a dual-generator strategy, framed as a way to increase throughput of patient doses in a nuclear medicine workflow (PMID 42344682). Work of this kind treats edotreotide as a manufacturing substrate, and it is why quality-control endpoints such as radiochemical purity appear so often alongside the term (PMID 40358768).

What the Published Literature Reports

Imaging studies

Several analyses have asked whether the amount of receptor-positive tissue seen on an edotreotide PET scan carries prognostic information. A 2023 study examined ⁶⁸Ga-edotreotide PET/CT somatostatin-receptor tumour volume in patients with primary gastroenteropancreatic neuroendocrine tumours and reported that this volume measurement predicted outcome (PMID 36714951). A later report extended the same question to the metastatic setting, assessing ⁶⁸Ga-edotreotide PET/CT somatostatin-receptor total tumour volume as a predictor of outcome in patients with metastatic gastroenteropancreatic neuroendocrine tumours (PMID 41572131).

Therapeutic studies

The earliest large clinical dataset in this glossary entry comes from a study of ⁹⁰Y-edotreotide in patients with metastatic carcinoid that was refractory to octreotide, published in the Journal of Clinical Oncology in 2010 (PMID 20194865). More recently, the COMPETE trial was reported as a phase 3, multicentre, randomised, open-label superiority trial comparing [¹⁷⁷Lu]Lu-edotreotide with everolimus in gastroenteropancreatic neuroendocrine tumours (PMID 42392118). A parallel randomised trial, LEVEL (GETNE T-2217), was described as evaluating the impact on survival and quality of life of ¹⁷⁷Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumours of the lung and thymus (PMID 40186126).

Finally, a systematic review and meta-analysis pooled the published experience with [¹⁷⁷Lu]Lu-edotreotide ([¹⁷⁷Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumours, addressing efficacy and safety together (PMID 41204752). Readers who want the numerical results — response rates, survival estimates and event frequencies — will find them in the full text of each source publication rather than summarised here.

Safety and Tolerability: What Studies Report

Safety with edotreotide is inseparable from the isotope attached to it, since the peptide is a carrier and the radiation dose comes from the metal. The systematic review and meta-analysis of [¹⁷⁷Lu]Lu-edotreotide in neuroendocrine tumours was framed explicitly around both efficacy and safety, indicating that pooled adverse-event reporting was one of its stated objectives (PMID 41204752). The randomised comparisons against everolimus were likewise designed to collect comparative outcome data in defined tumour populations — gastroenteropancreatic in COMPETE (PMID 42392118) and lung and thymus, with quality of life as a stated endpoint, in LEVEL (PMID 40186126). Radiolabelled edotreotide preparations are handled in licensed nuclear medicine facilities under radiation-protection rules; they are not consumer products, and this page names no doses because dosing decisions belong to treating clinicians and regulatory labelling, not to a glossary.

Terms Readers May See Alongside It

• DOTATOC — the same molecule, chemical shorthand (PMID 41204752).
• PRRT — peptide receptor radionuclide therapy, the treatment category into which lutetium-177 and yttrium-90 labelled edotreotide fall (PMID 20194865).
• SSTR — somatostatin receptor, the binding target quantified in the PET tumour-volume analyses (PMID 36714951).
• Somakit-TOC — a kit designation appearing in radiochemistry work on the gallium-68 labelled preparation (PMID 40358768).

In short, edotreotide is best understood not as a standalone "peptide compound" but as a targeting peptide engineered to carry a radioactive payload, and the literature about it is largely nuclear-medicine literature: imaging performance, radiochemistry and quality control, and randomised oncology trials.

References

• Edotreotide Gallium Ga-68 (2006)
• Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors (Journal of Neuroendocrinology, 2026)
• A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217) (BMC Cancer, 2025)
• 90Y-edotreotide for metastatic carcinoid refractory to octreotide (Journal of Clinical Oncology, 2010)
• [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial (Lancet, 2026)
• Ga-68-Edotreotide PET/CT SSTR Total Tumor Volume as a Predictor of Outcome in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (Cancer Control, 2026)
• Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors (Cancer Control, 2023)
• Optimization of radiochemical purity assessment for [68Ga]Ga-EDOTREOTIDE (Somakit-TOC): a shortened r-TLC method for improved PET radiopharmaceutical workflow (EJNMMI Radiopharmacy and Chemistry, 2025)
• Scalable 68Ga Cold Kit Radiolabeling: High-Throughput Preparation of [68Ga]Ga-Edotreotide via Aliquoting and Dual Generator Strategy (World Journal of Nuclear Medicine, 2026)